A retrospective, safety study of nivolumab and pembrolizumab in patients with advanced melanoma

Trial Profile

A retrospective, safety study of nivolumab and pembrolizumab in patients with advanced melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2017 Results published in the Investigational New Drugs
    • 01 Dec 2016 New trial record
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top